InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,424.00
(
0.11%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.79
(
1.05%
)
Bitcoin
65,115.03
(
-2.14%
)
Post# of 252253
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119875
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biomaven0 post# 119064

Thursday, 04/28/2011 9:37:05 PM

Thursday, April 28, 2011 9:37:05 PM

Post# of 252253

REGN—So this particular trial does not directly support every-other-month treatment for Lucentis.

I respectfully submit that you’re looking at the situation backwards. Bimonthly dosing (after the initial loading period) is already the de facto SoC for Lucentis in AMD, and the CATT study produced no data to change this. So, like it or not, bimonthly dosing of Lucentis is what Trap will have to compete against in the real world.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up